checkAd

     408  0 Kommentare Shire Extends Tender Offer for ViroPharma - Seite 2

    Copies of these materials and any documentation relating to the tender offer are not being, and must not be, directly or indirectly, mailed or otherwise forwarded, distributed or sent in, into or from any jurisdiction where to do so would be unlawful.

    FORWARD - LOOKING STATEMENTS

    Statements included in this announcement that are not historical facts are forward-looking statements. Forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, that:

    • Shire's proposed acquisition of ViroPharma may not be consummated due to the occurrence of an event, change or other circumstances that gives rise to the termination of the merger agreement;
    • a governmental or regulatory approval required for the proposed acquisition of ViroPharma may not obtained, or may be obtained subject to conditions that are not anticipated, or another condition to the closing of the proposed acquisition may not be satisfied;
    • ViroPharma may be unable to retain and hire key personnel and/or maintain its relationships with customers, suppliers and other business partners pending the consummation of the proposed acquisition by Shire, or ViroPharma's business may be disrupted by the proposed acquisition, including increased costs and diversion of management time and resources; and
    • difficulties in integrating ViroPharma into Shire may lead to the combined company not being able to realize the expected operating efficiencies, cost savings, revenue enhancements, synergies or other benefits at the time anticipated or at all;

    and other risks and uncertainties detailed from time to time in Shire's or ViroPharma's filings with the U.S. Securities and Exchange Commission, including their respective most recent Annual Reports on Form 10-K.

    For further information please contact:

    Investor Relations
    Eric Rojas, erojas@shire.com, +1-781-482-0999
    Sarah Elton-Farr, seltonfarr@shire.com, +44-1256-894157

    Media
    Jessica Mann, jmann@shire.com, +44-1256-894-280
    Gwen Fisher, gfisher@shire.com, +1-484-595-9836

    Seite 2 von 2



    PR Newswire (engl.)
    0 Follower
    Autor folgen

    Verfasst von PR Newswire (engl.)
    Shire Extends Tender Offer for ViroPharma - Seite 2 DUBLIN, December 27, 2013 /PRNewswire/ - Shire plc (LSE: SHP, NASDAQ: SHPG) announces that it has extended the expiration of its previously announced tender offer by a wholly owned subsidiary of Shire for all of the outstanding common shares of …